OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet Rheumatology is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Real-world evidence for prehospital COVID-19 treatment in systemic autoimmune rheumatic disease	1752
Research in Brief	1466
Brachial plexopathy: an unusual manifestation of Takayasu arteritis	571
Can contextual factors improve clarity of the results from clinical trials of low back pain?	365
A disseminated gonococcal infection with spinal locations	262
Biological disease-modification in axial spondyloarthritis: insights from MRI	229
Thrombotic microangiopathy as a presentation of anti-synthetase syndrome	112
Molecular signature-based decision making in the era of targeted therapies for systemic lupus erythematosus	111
Dual JAK and ROCK inhibition with CPL'116 in patients with rheumatoid arthritis with inadequate response to methotrexate: a randomised, double-blind, placebo-controlled, phase 2 trial	104
Reigniting the burnt-out health-care workforce	103
Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands	99
Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study	98
1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial	90
Three-dimensional, in-vitro approaches for modelling soft-tissue joint diseases	82
Patient involvement in digital rheumatology: lessons from practice	82
Pathways driving tendinopathy and enthesitis: siblings or distant cousins in musculoskeletal medicine?	81
Women in rheumatology in Africa	75
Aligning approaches to rheumatoid arthritis drug development: a comparison of FDA and EMA guidance	72
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?	70
Research in Brief	67
Outdoor temperatures and Raynaud's phenomenon in patients with systemic sclerosis	66
Assessing glucocorticoid toxicity: are the measures sensitive enough?	66
Correction to Lancet Rheumatol 2026; 8: e5–6	64
Biosimilars and the era of interchangeability	59
Preload deficiency as a treatable cause of fatigue and exercise intolerance in SLE	54

Interleukin-5 inhibition in eosinophilic granulomatosis with polyangiitis: time for another approach?	53
Proof-of-concept studies in axial spondyloarthritis: there are no shortcuts	52
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study	52
Reclassifying ANCA-associated vasculitis: a focus on kidney disease	49
Beyond MRI positivity in axial spondyloarthritis: the ubiquity of bone marrow oedema and risk of overinterpretation	48
First-line biological versus conventional synthetic disease-modifying antirheumatic drug therapy in adult-onset Still's disease: a multicentre, retrospective, propensity weighted cohort study	48
Sex as a predictor of clinical phenotype and determinant of immune response in IgG4-related disease: a retrospective study of patients fulfilling the American College of Rheumatology–European League A	47
Addition of aerobic physical activity to resistance exercise for hip osteoarthritis (PHOENIX): a randomised comparative effectiveness trial	47
Pain in clinical trials for knee osteoarthritis: estimation of regression to the mean	46
The association of outdoor temperature and self-reported Raynaud's phenomenon severity among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study	45
Baricitinib and ruxolitinib use through the UK HLH Network	44
Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis	43
When and how chronicity develops in rheumatoid arthritis: towards a temporal and tissue-integrated perspective	43
Artificial intelligence and high-dimensional technologies in the theragnosis of systemic lupus erythematosus	42
Urgent reform needed for homecare medicines services	41
Additional SARS-CoV-2 vaccine doses: a little is better than none	41
Clinical trial design: time to accelerate the pace of change?	41